drug-resistant epilepsy
Metabolic · 2012–2021
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| high fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate Ketogenic diet support for infants and children with epilepsy or other conditions requiring ketogenic diet management. | Mar 2021 | Recommended with restriction | none received |
| lacosamide Add-on therapy for partial onset seizures and secondarily generalised seizures in patients with drug-resistant epilepsy aged 16 years or older. | Nov 2012 | Recommended with restriction | no section in document |
What the PBS pays
$33M in government benefit over 2024–25, across 141,887 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| high fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | $17.6M |
| lacosamide | $15M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.